CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:An immunocompetent bone marrow-on-a-chip model for studying human hematological malignancies and preclinical therapeutic screening.
An immunocompetent bone marrow-on-a-chip model for studying human hematological malignancies and preclinical therapeutic screening.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
白血病及其他骨髓相关血液系统恶性肿瘤的复杂病理生理学凸显了对免疫活性骨髓模型的迫切需求,此类模型能够准确再现关键疾病微环境和患者治疗反应。现有骨髓模型往往缺乏再现患者特异性病理生理学或模拟体内免疫反应复杂动态所需的保真度。这一局限性最终限制了其在白血病免疫治疗开发等关键领域的应用。
在此,为克服这一挑战,我们提出了一份详细方案,用于构建3D微流控人骨髓芯片微生理系统,该系统可再现天然组织的解剖结构和功能。其同心三腔室设计复制了骨髓的空间结构,在血管化微环境中共培养基质细胞和造血细胞,以建立生理相关且具有免疫活性的微环境。为模拟患者特异性生物学,该平台整合了患者来源样本,从而能够对CAR-T 细胞治疗和化疗等治疗干预进行个性化评估。该平台通过活细胞成像、免疫荧光、细胞因子谱分析、流式细胞术和单细胞测序支持多重读数,从而能够对治疗反应进行全面分析。该方案需要约7 d建立功能性骨髓芯片,包括微流控装置制造(1 d)、细胞接种(1 d)和骨髓模型的逐步开发(5 d)。治疗测试在可变时间范围内进行,通常为2 d至14 d。该方案面向具有细胞培养和荧光成像基础经验、并具备基本微流控制造和组织培养经验的研究人员。
The complex pathophysiology of leukemia and other bone marrow-related hematological malignancies underscores the critical need for immunocompetent bone marrow models that can accurately recapitulate key disease microenvironment and patient therapeutic responses. Existing bone marrow models often lack the fidelity required to recapitulate patient-specific pathophysiology or to emulate the intricate dynamics of in vivo immune responses. This limitation ultimately constrains their utility in critical areas such as leukemia immunotherapy development.
Here, to overcome this challenge, we present a detailed protocol for building a 3D microfluidic human bone marrow-on-a-chip microphysiological system that recapitulates the anatomical organization and function of the native tissue. Its concentric three-compartment design replicates the marrow's spatial architecture, co-culturing stromal and hematopoietic cells within a vascularized niche to establish a physiologically relevant, immunocompetent microenvironment. To model patient-specific biology, the platform incorporates patient-derived samples, enabling the personalized evaluation of therapeutic interventions such as chimeric antigen receptor T cell therapy and chemotherapy.
The platform supports multiplexed readouts through live imaging, immunofluorescence, cytokine profiling, flow cytometry and single-cell sequencing, enabling a comprehensive analysis of treatment response. The protocol requires ~7 d to establish the functional bone marrow chip, comprising microfluidic device fabrication (1 d), cell seeding (1 d) and progressive development of the bone marrow model (5 d).
Therapeutic testing is conducted over a variable timeframe, typically ranging from 2 d to 14 d. The protocol is designed for researchers with basic experience in cell culture and fluorescence imaging,who have basic microfluidics fabrication and tissue culture experience.
MEMBER ACCOUNT
登录成功会直接打开下一页。